AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
← catalyst calendarNCT07571005 · readout in 693 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
300estimated
Sites
80
Countries
Australia, China, Denmark +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-05 | actual | When the study began enrolling |
| Primary completion | 2028-07-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-04 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
- Obstructive Sleep Apnoea
Interventions
- Drug: NNC0487-0111
- Drug: Placebo (matched to NNC0487-0111)
Primary outcomes
what the primary-completion date above is the date OFRelative change in body weight
measured From baseline (week 0) to (week 80)
Change in apnoea-hypopnoea index (AHI)
measured From baseline (week 0) to (week 80)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed